Previous 10 | Next 10 |
NEEDHAM, Mass., Dec. 19, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it has been selected for addition to the NASDAQ Biotechnology In...
WALTHAM, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer, and William Ludlam, M.D., P...
WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that William Ludlam, M.D., Ph.D., Senior Vice President of Clinical D...
The following slide deck was published by Chiasma, Inc. in conjunction with this Read more ...
Chiasma, Inc. (CHMA) Q3 2019 Results Earnings Conference Call November 05, 2019, 05:00 PM ET Company Participants Dawn Schottlandt - Investor relations Raj Kannan - Chief Executive Officer Bill Ludlam - Senior Vice President-Clinical Development and Medical Affairs Mark Fitzpat...
Image source: The Motley Fool. Chiasma Inc (NASDAQ: CHMA) Q3 2019 Earnings Call Nov 5, 2019 , 5:00 p.m. ET Operator Continue reading
Chiasma (NASDAQ: CHMA ): Q3 GAAP EPS of -$0.20 beats by $0.01 . More news on: Chiasma, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
CHIASMA OPTIMAL trial, conducted under SPA and designed to support FDA approval, met the primary and all secondary endpoints MYCAPSSA ® NDA on track for submission by year-end 2019 MPOWERED TM Phase 3 trial, designed to support EU approval, progressing as planned with top...
WALTHAM, Mass., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (Nasdaq: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that it will host a conference call and live audio webcast on Tuesday...
WALTHAM, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a clinical-stage biopharmaceutical company focused on improving the lives of patients with rare and serious chronic diseases, today announced that Raj Kannan, Chief Executive Officer and Dr. William Ludlam, Sen...
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix appoints Director Anand Varadan PR Newswire LEXINGTON, Mass. , July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and...
NEEDHAM, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives ...
NEEDHAM, Mass., May 27, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”) today presented patient-reported outcomes (PROs) data from its MPOWERED™ Phase 3 trial demonstrating that study patients with acromegaly reported si...